不能分类的骨髓增生异常/骨髓增殖性疾病转化为急性髓系白血病2例并文献复习

详细信息

收稿日期: 2013-01-17

Two cases of myelodysplastic/myeloproliferative neoplasms-unclassified evolving into acute myelogenous leukemia and literature review

More Information

Received Date: 17 January 2013

摘要: 目的：探讨不能分类的骨髓增生异常/骨髓增殖性疾病（MDS/MPN-U）的临床特点、诊断、治疗及预后。方法：对2例MDS/MPN-U的临床资料进行分析总结，并结合近年来国内外文献进行讨论。结果：MDS/MPN-U具有混合性MPN和MDS特征而不能归为任何一种MDS、MPN或MDS/MPN亚型，高风险转化为急性髓系白血病，化疗及放疗效果较差，生存期较短。结论：MDS/MPN-U是一类少见的血液系统恶性疾病，其最终可能发展为急性髓系白血病。
- 骨髓增生异常综合征 /
- 不能分类的骨髓增生异常/骨髓增殖性疾病 /
- 急性髓系白血病
Abstract: Objective: To explore the clinic feature,diagnose,treatment and prognosis of myelodysplastic/myeloproliferative neoplasms-unclassified (MDS/MPN-U).Method: Two patients with MDS/MPN-U were reported and related literature were reviewed.Result: MDS/MPN-U showed features of both MDS and MPN but didn't meet the criteria for any of the three major MDS/MPN entities,with higher-risk evolving into acute myelogenous leukemia,poor response to radiation therapy and chemotherapy and shorter life expectancy.Conclusion: MDS/MPN-U is a kind of rare malignant diseases which may progress to become acute myelogenous leukemia.
- myelodysplastic syndromes /
- myelodysplastic/myeloproliferative neoplasms-unclassified /
- acute myelogenous leukemia

[1]	VARDIMAN J W.The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues:an overview with emphasis on the myeloid neoplasms[J].Chem Biol Interact,2010,184:16-20.
[2]	CANNELLA L,BRECCIA M,LATAGLIATA R,et al.Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification[J].Leuk Res,2008,32:514-516.
[3]	THEPOT S,ITZYKSON R,SEEGERS V,et al.Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine:a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)[J].Blood,2010,116:3735-3742.
[4]	BEJANYAN N,TIU R V,RAZA A,et al.A phase 2 trial of combination therapy with thalidomide,arsenic trioxide,dexamethasone,and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)[J].Cancer,2012,118:3968-3976.
[5]	CHUNG E,HSU C L,KONDO M,et al.Constitutive MAP kinase activation in hematopoietic stem cells induces a myeloproliferative disorder[J].PLoS One,2011,6:e28350.